Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.

Manufacturing

Pharmaceutical

Harrow

Mark L. Baum

Garrett S.

Mark Mannebach

Kim Barratt

Dennis E. Saadeh

Andrew R. Boll

John P. Saharek

The Leadership Team at Harrow is responsible for setting the strategic direction, overseeing corporate governance, and ensuring the achievement of business objectives. This team guides the company in the discovery, development, and commercialization of innovative ophthalmic therapies, while fostering talent, managing financial health, and expanding market presence to maintain Harrow’s leadership in the eyecare pharmaceutical industry.

Leadership Team

Sales and Marketing

Leadership Team

About

Team members

Other teams at Harrow

Sales and Marketing